WeightWatchers (WW) reports earnings tomorrow: what to expect

WeightWatchers (WW) reports earnings Thursday. Last quarter, revenue was $162.3M, down 14.2% YoY, beating EPS but missing EBITDA estimates. Analysts expect this quarter's revenue to decline 11.5% YoY. WW trades at $12.66, with an average price target of $27.50.

Original reporting
Published Nov 4, 2026, 3:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 3:46 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
WeightWatchers (WW) reports earnings tomorrow: what to expect — source image
Decision brief

The 30-second read

$WWNeutralMed
01

Why it matters

Traders can use the cited consensus revenue decline and the prior-quarter EBITDA miss to form scenarios for whether the upcoming report confirms deterioration or shows stabilization.

02

Market read

WW’s earnings timing and the consensus expectation of continued revenue decline make this a near-term volatility setup, but the article itself is largely a preview rather than a new disclosure.

03

What to watch

The article does not discuss guidance, cash flow, subscriber/retention metrics, or cost initiatives, which are often the real drivers of post-earnings repricing for wellness/consumer services models.

Relevance 4/10Novelty 4/10Timing: pre-market Thursday earnings release

Background

The article frames WW’s upcoming earnings as a near-term decision point, referencing last quarter’s revenue/EPS/EBITDA outcomes and current consensus expectations.

Company-level read

Ticker impact

$WWNeutralMedium confidence
Context

WeightWatchers (WW) is set to report earnings Thursday before the bell, with the article citing recent revenue/EPS/EBITDA expectations and estimate reconfirmations.

Expected impact

Likely two-way volatility around the open as traders reprice the revenue decline expectation and any EBITDA margin/trajectory signals from the upcoming report.

Evidence & confidence

The piece provides pre-earnings positioning (consensus revenue decline, estimate reconfirmations, and prior-quarter revenue/EPS beat with EBITDA miss), but it does not disclose new guidance or a fresh catalyst beyond the scheduled earnings event.

Market effects

Limited read-through to the specialized consumer services peer group, since the article mainly uses peers as context rather than reporting new sector-wide developments.

Primarily US-focused via a single-company earnings catalyst; no cross-market policy or macro shock is cited.

Low, as the story is company-specific and does not reference global regulatory or supply-chain events.

Counterpoint

If WW’s revenue decline moderates or EBITDA stabilizes versus the prior-quarter miss, the stock could outperform despite the consensus YoY revenue contraction.

Key entities

  • WeightWatchers

    NASDAQ-listed wellness company scheduled to report earnings Thursday before the bell.

  • ADT

    Peer cited as having delivered revenue growth and an earnings beat (used as context, not the subject).

  • Pool

    Peer cited as having reported revenue growth and a post-results stock move (used as context, not the subject).

  • Nvidia

    Mentioned in a promotional line unrelated to WW’s earnings catalyst.

Related articles

$WWMedAI 8/10

What WW International (WW) Said on Its Q3 Earnings Call

WW International reported Q3 earnings, highlighting a 40% YoY increase in clinical subscribers to 174,000, though down from 197,000 in Q2. Behavioral subscription revenue fell 22% to $113.9M, while clinical revenue rose 48% to $38M. Adjusted gross margin reached 74.6%, and marketing expenses declined. The company narrowed its 2026 revenue guidance to $625M-$630M and adjusted EBITDA to $110M-$115M. Cash increased to $126.4M, and debt was reduced by 70%.

$WWMedAI 8/10

WW International Inc (WW) (Q3 2026) Earnings Call Highlights: Clinical Revenue Surges 48%

WW International reported Q3 2026 revenue of $152.9M, down 11% YoY, with behavioral subscription revenue dropping 22%. Clinical revenue surged 48%, but clinical subscribers declined sequentially. Full-year revenue guidance was narrowed to $625-$630M. Core+ subscribers grew 16% YoY, driven by GLP-1 program adoption and virtual experiences. The company expects flat gross margins at ~74% despite clinical mix growth.

$WWMed

WW International, Inc. Q3 2026 Earnings Call Summary

WW International reported Q3 2026 earnings, highlighting a strategic shift to higher-value tiers (Core+ and Med+) generating 50% of revenue. Clinical revenue grew 48% YoY, driven by Med+ and GLP-1 Success Program. Core+ saw subscriber growth for four consecutive quarters. The company expects sustainable growth in 2027, with clinical revenues projected to reach 25% of total revenue. Debt reduced by 70% since 2025, and net income turned positive.